Drug intelligence / Profile preview

SAAVI DNA-C2

Development stage: Phase 1
Lead developer: South African AIDS Vaccine Initiative
Modality: DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

SAAVI DNA-C2 is an HIV-1 subtype C DNA vaccine developed in South Africa. It consists of two DNA plasmids: one expressing a polyprotein Grttn (fusion of HIV-1 subtype C Gag, reverse transcriptase, Tat and Nef) and another expressing HIV-1 subtype C truncated envelope protein (Env, gp150). All sequences are codon-optimized for high expression and modified for human safety. The vaccine is designed to be administered intramuscularly as part of a prime-boost strategy, typically followed by SAAVI MVA-C vaccine.

Targets

Human immunodeficiency virus type 1 (HIV-1) subtype C antigens

Beyond the preview

Go deeper on SAAVI DNA-C2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SAAVI DNA-C2.

Explore the full profile